June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Safety of DuraSite vehicle as part of a topical treatment in cataract surgery patients
Author Affiliations & Notes
  • Judith Hutcheson
    InSite Vision, Alameda, CA
  • Lyle Bowman
    InSite Vision, Alameda, CA
  • Kamran Hosseini
    InSite Vision, Alameda, CA
  • Footnotes
    Commercial Relationships Judith Hutcheson, InSite Vision (E); Lyle Bowman, InSite Vision (E); Kamran Hosseini, InSite Vision Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1093. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Judith Hutcheson, Lyle Bowman, Kamran Hosseini; Safety of DuraSite vehicle as part of a topical treatment in cataract surgery patients. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1093.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To investigate the safety of DuraSite vehicle (polycarbophil, sodium chloride, edetate disodium dihydrate, and sterile water for irrigation) in post cataract surgery patients.

Methods: In a well-controlled multicenter Phase II clinical trial, 169 patients were randomized into 4 different groups to investigate different dosing regimens of Bromfenac in DuraSite 0.075% (ISV-303) compared with the non DuraSite based commercial Bromfenac formulation (0.09%). DuraSite was the vehicle (either with or without the drug) in three arms of the study (approximately 3/4 of the total patients, n=127). All patients received the investigational medication one day after cataract surgery, and self-administered the formulation b.i.d. for a period of two weeks. Slit-lamp biomicroscopy, IOP measurement and visual acuity test were performed on 4 clinical visits while ophthalmoscopy was performed on Days 1 and 29. All patients received a safety examination at Days 8, 15 and 30 post dosing.

Results: The incidence of adverse events for all DuraSite containing arms, ISV-303 BID, ISV-303 QD and DuraSite Vehicle BID was comparable to the active control of commercial Bromfenac 0.09% BID. No major differences were observed in BCVA, IOP, or ophthalmoscopy evaluations.

Conclusions: DuraSite-containing ophthalmic formulations are well tolerated for use in cataract surgery patients as shown in a well-controlled multicenter clinical trial.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 445 cataract  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.